BTG is to acquire Biocompatibles, the Farnham-based supplier of drug devices, for £156m. [22-Nov-2010]
BTG has sold VisionTec, the contact lens technology company, to 1-800 Contacts of the US, and the business will be renamed Clearlab UK. [03-Mar-2004]
BTG is to raise £27m in a rights issue to fund the commercial development of its Varisolve treatment for varicose veins. [13-Feb-2004]
BTG is forming a joint venture with Croda Chemicals to manufacture the active ingredient in Varisolve, a new treatment for varicose veins. [24-Nov-2000]
BTG, the intellectual property manager, is planning to raise £121m in a rights issues, in order to set up a separate biotechnology group, expand into North America and fund joint ventures with other technology companies. [29-Sep-2000]
BTG, the intellectual property manager, is planning to invest £25m over the next five years on clinical trials for its Varisolve treatment for varicose veins. [08-Jun-2000]
BTG, the intellectual property manager, is launching the BeneFix treatment for haemophilia in the UK and Europe, and it will be distributed through Baxter Healthcare. [28-Jan-1999]
BTG is to raise £50m in a share placing for its Torotrak vehicle transmissions business, in a move that will give Torotrak greater independence as it further develops the fuel-efficient gearless transmission. [05-Jun-1998]
BTG has reached agreement to licence its patented two-part hip cup to Howmedica, a division of Pzifer of the US. [28-Jan-1998]
BTG is to raise £25m in a share placing in order to fund the development of Torotrak, its infinitely variable transmission system which has already been licensed to Toyota, Ford and Getrag. [30-May-1997]
BTG has licensed an animal allergy vaccine to Peptide Therapeutics, who is in discussions with major companies about the commercialisation of the vaccine for use with pets. [05-Nov-1996]
BTG has signed a worldwide development and marketing deal with Forest Laboratories of the US for a new painkiller that combines oxycodone with ibuprofen. [29-Aug-1996]